A pharmacogenetic strategy for immunosuppression based on the CYP3A5 genotype.
Pharmacogenetics has the potential to complement therapeutic drug monitoring in achieving target blood concentrations of the immunosuppressive drugs during the critical early period after transplantation when adequate drug exposure is essential to prevent rejection. The most attractive candidate for a pharmacogenetic strategy is tacrolimus dosing based on the CYP3A5 genotype.
MacPhee
Iain A M
IA
Cellular and Molecular Medicine, Renal Medicine, St. George's, University of London, Cranmer Terrace, London, UK. imacphee@sgul.ac.uk
Holt
David W
DW
D044466:Asian People / Q000235:genetics; D044383:Black People / Q000235:genetics; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics*; D015971:Gene Expression Regulation, Enzymologic; D005838:Genotype; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016559:Tacrolimus / Q000627:therapeutic use; D014181:Transplantation Immunology; D006113:United Kingdom; D044465:White People / Q000235:genetics
D007166:Immunosuppressive Agents; D003577:Cytochrome P-450 Enzyme System; C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D016559:Tacrolimus